Read More Pharma Industry News AHA 2025 spotlight: sotagliflozin data spark debate on benefits in HFpEF patients without diabetes Find out how sotagliflozin’s debated HFpEF results at AHA 2025 could change heart-failure therapy beyond diabetes. bySoujanya RaviNovember 9, 2025